<SEC-DOCUMENT>0001213900-23-094884.txt : 20231212
<SEC-HEADER>0001213900-23-094884.hdr.sgml : 20231212
<ACCEPTANCE-DATETIME>20231212080225
ACCESSION NUMBER:		0001213900-23-094884
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231211
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231212
DATE AS OF CHANGE:		20231212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTENSITY THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001567264
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461488089
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41109
		FILM NUMBER:		231479996

	BUSINESS ADDRESS:	
		STREET 1:		61 WILTON ROAD, 3RD FLOOR
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880
		BUSINESS PHONE:		203-221-7381

	MAIL ADDRESS:	
		STREET 1:		61 WILTON ROAD, 3RD FLOOR
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Intensity Therapeutics, Inc.
		DATE OF NAME CHANGE:	20130117
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea189864-8k_intensity.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:INTS="http://intensitytherapeutics.com/20231211">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_INTS_intensitytherapeutics.com_20231211 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20231211_20231211 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001567264 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityCentralIndexKey">0001567264</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ints-20231211.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-12-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567264</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-11</xbrli:startDate>
        <xbrli:endDate>2023-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20231211__20231211_zCGDLgFNIPPj"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90B_edei--DocumentPeriodEndDate_c20231211__20231211_zNJ7r5V5mADk"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 11, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20231211__20231211_zbZ8ND903t07"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityRegistrantName">Intensity Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in Its
Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20231211__20231211_zzdmBOihllJh"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityFileNumber_c20231211__20231211_zh5GA2KKw6Ph"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityFileNumber">001-41109</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20231211__20231211_zAJ7jI0IG1df"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityTaxIdentificationNumber">46-1488089</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or Other Jurisdiction<br />
of Incorporation)</b></p></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Commission&#160;File Number)</b></span></td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(IRS Employer<br />
Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityAddressAddressLine1_c20231211__20231211_zt1vR5Jp56wd"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityAddressAddressLine1">1 Enterprise Drive</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressAddressLine2_c20231211__20231211_zqKBWI1SMvl"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityAddressAddressLine2">Suite 430</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20231211__20231211_zSDD2QO9n5Ld"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityAddressCityOrTown">Shelton</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20231211__20231211_zKeo2BlDDZi8"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityAddressStateOrProvince">CT</ix:nonNumeric></span></b></p></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressPostalZipCode_c20231211__20231211_zjziLoaDWoq8"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:EntityAddressPostalZipCode">06484-4779</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Address of Principal Executive Offices)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20231211__20231211_zJd7gVNHbMgc"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:CityAreaCode">203</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20231211__20231211_z8NGiZ8IijUc"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:LocalPhoneNumber">221-7381</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s Telephone Number, Including
Area Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span>Not Applicable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instructions A.2. below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--WrittenCommunications_c20231211__20231211_zDdQ0S2j2de3"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SolicitingMaterial_c20231211__20231211_zNVpdHKZZg4j"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20231211__20231211_zgvBscRym8H5"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementIssuerTenderOffer_c20231211__20231211_zjKE97I2SDl3"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class:</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbol(s):</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of Exchange on Which Registered:</b></span></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_902_edei--Security12bTitle_c20231211__20231211_zgg2Sog0T3Ug"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--TradingSymbol_c20231211__20231211_zmP7C0ozHqP"><ix:nonNumeric contextRef="AsOf2023-12-11" name="dei:TradingSymbol">INTS</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><b><span>The <span id="xdx_900_edei--SecurityExchangeName_c20231211__20231211_z9X64eU30uC7"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20231211__20231211_z1g6yHyouvlc"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--EntityExTransitionPeriod_c20231211__20231211_zhWIbHr4T7a5"><ix:nonNumeric contextRef="AsOf2023-12-11" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>Item&#160;5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Appointment of Joseph Talamo</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On December 11, 2023, Intensity Therapeutics
(the &#8220;Company&#8221;), appointed Joseph Talamo to serve as the Chief Financial Officer of the Company effective December 11, 2023.
Prior to joining the Company, from August 2020 until November 2023, Mr. Talamo, age 54, served as Senior Vice President and Chief Financial
Officer of HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse and metastasis. From
June 2011 until July 2020, Mr. Talamo was employed by Lisata Therapeutics, Inc. (formerly known as Caladrius Biosciences,
Inc.) where he served in various roles, including Corporate Controller and Chief Accounting Officer, and then later as the Company&#8217;s
Senior Vice President and Chief Financial Officer. Mr. Talamo received a B.B.A. in Accounting from Hofstra University, and an M.B.A. in
Finance from Hofstra University. Mr. Talamo is a Certified Public Accountant in the State of New York.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">There are no arrangements or understandings
between Mr.&#160;Talamo and any other person pursuant to which he was selected as an officer, and there are no family relationships between
Mr.&#160;Talamo and any of the Company&#8217;s directors or executive officers. Mr.&#160;Talamo has no direct or indirect material interest
in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation&#160;S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Summary of Material Terms of Joseph&#8217;s
Employment Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Company and Mr.&#160;Talamo entered into
an employment agreement (the &#8220;Employment Agreement&#8221;) in connection with his appointment as Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Employment Agreement provides, Mr.&#160;Talamo
with the following compensation for his services beginning effective December 11, 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">a base salary of $370,000 per
year (&#8220;Base Salary&#8221;);</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-size: 10pt">eligibility to earn a target
bonus of up to 35% of Base Salary based on Mr. Talamo&#8217;s performance and the performance of the Company during the calendar year;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-size: 10pt">a grant of 80,000 options to
purchase the Company&#8217;s common stock, with an exercise price of $6.88, which vest, subject to Mr.&#160;Talamo&#8217;s continuing
employment with the Company, in four equal, annual installments, beginning one year from the grant date;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">participation in employee health
benefits; and</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-size: 10pt">reimbursement for all reasonable
travel, entertainment and other business expenses.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Following three months of employment at the
Company, if the Company terminates Mr.&#160;Talamo&#8217;s employment without Cause (as defined in the Employment Agreement) or Mr. Talamo
voluntarily terminates his own employment for Good Reason (as defined in the Employment Agreement), Mr.&#160;Talamo will be entitled to
receive an amount equal to 1 month of Base Salary during his first year of employment and an additional 1 month of Base Salary following
each year of his employment anniversary, up to a maximum amount of 6 months of Base Salary. If the Company terminates Mr. Talamo for Cause
(as defined in the Employment Agreement) or Mr. Talamo terminates his employment without Good Reason, no such severance will be paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If Mr. Talamo is terminated without Cause or resigns for Good Reason
on or within six months after a Change in Control (as defined in the Employment Agreement), he will receive an amount equal to 4 months
of Base Salary following his one year employment anniversary, 5 months of Base Salary following his second year employment anniversary
and six months of Base Salary following his third year employment anniversary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Payment of post-employment benefits is contingent
upon Mr.&#160;Talamo&#8217;s due execution and delivery to the Company of a fully-executed general release of claims in a form satisfactory
to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Employment Agreement also includes provisions
regarding confidentiality, the assignment of intellectual property and a twelve-month&#160;non-compete&#160;and&#160;non-solicitation&#160;period
following expiration or termination of Mr.&#160;Talamo&#8217;s employment with the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The foregoing summary of the Employment Agreement
is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as exhibit
10.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><i>Interim Chief Financial Officer Departure</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="background-color: white">In June
2023, our Principal Accounting Officer and Controller, John Wesolowski, became our full-time&#160;Chief Financial Officer on an interim
basis. With the appointment of Mr. Talamo as the Company&#8217;s new Chief Financial Officer, Mr. Wesolowski will no longer serve in this
capacity but will continue on as the Company&#8217;s Principal Accounting Officer and Controller. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="background-color: white">A copy of the press release announcing
Mr.&#160;Talamo&#8217;s appointment of as Chief Financial Officer of the Company and Mr.&#160;Wesolowski&#8217;s departure as Interim
Chief Financial Officer is attached to this Form&#160;8-K&#160;as Exhibit 99.1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-size: 10pt"><b>Item&#160;9.01
Financial Statements and Exhibits.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt; background-color: white"><b><i>(d) Exhibits</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: left; width: 9%"><span style="font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 90%"><b>Description of Document</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">10.1</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea189864ex10-1_intensity.htm"><span style="font-size: 10pt"><span style="text-decoration: none">Employment Agreement with Joseph Talamo</span></span></a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top">99.1</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="ea189864ex99-1_intensity.htm">Press Release, dated December 12, 2023</a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: December 12, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>Intensity Therapeutics, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Lewis H. Bender</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"><span style="font-size: 10pt">Lewis H. Bender</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Signature Page to the Form 8-K</i>]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



















</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUrXevExqYgsRCJ6XXSKJd2R2c3sk/rLViUaBobh3nOvEDOxo62ukeG6LjI4Y9PWyiEUeENGU6J3pPtDAv4WeNfWsTJufH9gSp5Bz6zmMiy9MFo7bbFKIJKLKFrIGMI4kUvIjyIY9JTMTVdonFY1KFNBztSyRqf4PSWcVU+GmvdYdUG2moyPm4eT/AEZRhJO1KkX8cNClqUimI0TiB3Ts/WuTe/QDCRsamx8nZ3o/wZfAfFKhQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea189864ex10-1_intensity.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT WITH JOSEPH TALAMO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.55in 0pt 192.55pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYMENT
AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EMPLOYMENT
AGREEMENT (this &ldquo;Agreement&rdquo;) dated as of December 11, 2023, (the &ldquo;Effective Date&rdquo;), by and between INTENSITY
THERAPEUTICS, Inc., a Delaware corporation (&ldquo;INTENSITY&rdquo; or &ldquo;Company&rdquo;), and Joseph Talamo (the &ldquo;Employee&rdquo;)
with an address of 123 Harbor Drive, Unit 409; Stamford, CT 06902.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Employment</U>. INTENSITY hereby employs the Employee to serve as Chief Financial Officer at INTENSITY in accordance with the terms
and provisions of this Agreement, and the Employee hereby accepts such employment with INTENSITY. The first workday is anticipated to
be December 11, 2023.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Term</U>. The term of this Agreement shall commence on the Effective Date and shall continue until this Agreement is terminated as
hereinafter provided.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Compensation</U>. As compensation, including vacation and holidays, for all services rendered by the Employee to INTENSITY pursuant
to this Agreement, INTENSITY shall pay to the Employee the amounts noted in Schedule A of this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Employee Benefits</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Benefits Generally</U>. The Employee shall be entitled to receive and participate in such employee benefits as agreed with INTENSITY
and noted in schedule A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Indemnification Rights</U>. The Employee shall be entitled to indemnification, including advance reimbursement of travel expenses,
to the fullest extent permitted by applicable law, and shall be entitled to receive an indemnification agreement with terms equivalent
to any indemnification agreement that INTENSITY executes with any of its officers or directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Description of Duties</U>. During the term of this Agreement, the Employee shall:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Devote
for time as needed, professional skills, attention and energies to the fulfillment of the duties customarily associated with such position
and outlined in scheduled B, any special projects assigned by the CEO and the accomplishment of the goals provided by the Company to
the Employee from time to time; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Act
in accordance herewith, and in all accounts be responsible and responsive to the President and CEO (direct supervisor).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>General Services</U>. During the term of this Agreement, the Employee shall:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) Observe
INTENSITY&rsquo;s policies and standards of conduct, as well as customary standards of business conduct, including any standards prescribed
by law or regulation; or employment manual.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) Perform
his duties hereunder in a manner that preserves and protects INTENSITY&rsquo;s business reputation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) Do
all things and render such services as may be necessary or beneficial in carrying out any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7. <U>Nondisclosure
of Proprietary or Confidential Information and Confidential Communications.</U> The Employee recognizes and acknowledges that the marketing
plans, scientific data, intellectual property, know-how, scientific reports, analysis, business plans, databases, study results, preclinical
plans, clinical data, clinical plans, business strategy, the names and addresses of INTENSITY&rsquo;s customers, suppliers, business
partners, advisors, collaborators or investors, any trade secrets and any other confidential and proprietary information concerning the
business or affairs of INTENSITY including but not limited to scientific and technical information, marketing and business plans, budgets,
financial projections, employee information, banking information, financial statements, and strategies (hereinafter collectively referred
to as the &ldquo;Confidential Information&rdquo;) constitute a valuable, proprietary, special and unique asset of INTENSITY&rsquo;s business.
The Employee further recognizes and acknowledges that any communications, whether written, oral or otherwise, that INTENSITY or any of
INTENSITY&rsquo;s employees has with INTENSITY&rsquo;s existing or prospective customers, investors, vendors, accountants, partners,
collaborators and clients are extremely confidential (hereinafter the &ldquo;Confidential Communications&rdquo;). The term Confidential
Information shall exclude any information that has been made public through no fault of the Employee.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee shall not, for any reason whatsoever, during or after the termination of his employment with INTENSITY, use, disclose or allow
access to, for his own benefit or for that of another, the Confidential Information or the Confidential Communications (or any part thereof)
to any person, firm, corporation, association or other entity for any reason or for any purpose whatsoever.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a breach or threatened breach by the Employee of the provisions of this Section, INTENSITY shall be entitled to an injunction
restraining the Employee from so using, disclosing or allowing access to, in whole or in part, the Confidential Information and the Confidential
Communications or from rendering any services to any person, firm, corporation, association or other entity to whom the Confidential
Information or the Confidential Communications, in whole or in part, have been disclosed or are threatened to be disclosed. Nothing herein
shall be construed as prohibiting INTENSITY from pursuing any other remedies available to INTENSITY for such breach or threatened breach,
including, but not limited to, the recovery of damages and reasonable attorneys&rsquo; fees from the Employee.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
termination of this Agreement by either party for any reason, the Employee shall return to INTENSITY any of the Confidential Information,
Confidential Communications, charts, company literature, reports, employer credit cards or other proprietary materials of INTENSITY including
any laptop or purchased equipment then in the Employee&rsquo;s possession and all other materials of INTENSITY which the Company requests
the Employee to so return.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Section shall in all respects survive any termination of this Agreement and shall remain in full force and effect thereafter.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Covenant Not to Compete; Nonsolicitation of Employees and Customers</U>. The Employee agrees that during the Restricted Period, he
shall not directly or indirectly compete with INTENSITY. In construing the foregoing prohibition, except as described in the non-restricted
activities (the &ldquo;Non Restricted Activities&rdquo; defined below) the Employee shall be deemed to be competing with INTENSITY if
he shall become self-employed in, or accept employment with, consult with, render services to or become associated with, own, manage,
operate, join, control, or participate in the ownership, management, operation, or control of, or be connected in any material manner
with, or directly or indirectly enter into the employment of, or make a substantial investment in, any corporation, partnership, proprietorship
or other type of business organization or entity which engages in, a business (a &ldquo;Competing Business&rdquo;) involving activities
which directly and materially compete with the lines of business in or with which INTENSITY is then currently involved as defined. The
&ldquo;Restricted Period&rdquo; shall mean the period of the Employee&rsquo;s employment with INTENSITY pursuant to this Agreement plus
a period of one continuous year thereafter; <I>provided, however,</I> that if the Employee is terminated by INTENSITY without cause or
voluntarily terminates his own employment for Good Reason (as those terms are defined below), the Restricted Period shall be coincident
with the Post-Termination Period, as defined in Section 13A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Employee further agrees that during his employment with INTENSITY and for a period of one continuous year
thereafter he shall not solicit any of INTENSITY&rsquo;s employees, existing customers or prospective customers (of which the
Employee is then currently aware), affiliated research institutions or scientists, on behalf of himself or any Competing
Business.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Section 8 shall in all respects survive any termination of this Agreement and shall remain in full force and effect during the period
specified in this Section 8.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Assignment of Rights</U>. Any and all information, data, inventions, discoveries, materials, processes, notebooks and other work product
which the Employee conceives, develops, produces or acquires during his employment with INTENSITY, which directly or indirectly relates
to work performed for INTENSITY, shall be the sole and exclusive property of INTENSITY. The Employee shall promptly execute any and all
documents necessary and take such further actions as INTENSITY may deem necessary to assign any and all of the Employee&rsquo;s right,
title and interest in such property to INTENSITY.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Intellectual Property</U>. During the Employee&rsquo;s employment at INTENSITY, the Employee shall promptly assist with and execute
any and all applications, assignments or other documents which an officer or director of INTENSITY shall deem necessary or useful in
order to obtain and maintain patent, trademark, copywrite, or other intellectual property protection for INTENSITY&rsquo;s products or
services. After the termination date of his employment with INTENSITY, the Employee shall use reasonable efforts to assist INTENSITY
on intellectual property matters as they relate to his employment, and INTENSITY shall reasonably compensate the Employee for his time
and expense.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Documents, Records, etc</U>. All documents, records, data, apparatus, equipment and other physical property, whether or not pertaining
to Confidential Information, which are furnished to the Employee by INTENSITY or are produced by the Employee in connection with the
Employee&rsquo;s employment will be and remain the sole property of INTENSITY. The Employee will return to INTENSITY all such materials
and any property (including computers, hard drives, flash drives) as and when requested by INTENSITY. In any event, and whether or not
INTENSITY so specifically requests, the Employee will return all such materials and property immediately upon termination of the Employee&rsquo;s
employment for any reason. The Employee will not retain any such material or property or any copies thereof after such termination.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Non-Restricted Activities</U>. During the term of this Agreement, the Employee shall not engage in any business activities or ventures
competitive to the business activities of INTENSITY without the express prior written consent of INTENSITY&rsquo;s President; <I>provided,
however, </I>that nothing in this Agreement shall be construed as preventing the Employee from engaging in customary charitable activities.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Termination.</U></FONT></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Employee is considered an &ldquo;at will&rdquo; employee and Employee may be terminated by either INTENSITY or the Employee, at any time
for any or no reason. INTENSITY may determine the Employee&rsquo;s final day of employment hereunder. The date specified in any notice
of termination as the Employee&rsquo;s final day of employment shall be referred to herein as the &ldquo;Termination Date.&rdquo;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of the Employee&rsquo;s voluntary termination, then the Employee shall, at the request of the President of INTENSITY, continue
as an employee of INTENSITY for an additional thirty (30) day period after the Termination Date for the purpose of assisting INTENSITY
in locating and training a suitable replacement for the Employee. During such additional period, the Employee shall be entitled to full
compensation and any agreed upon benefits and the Employee shall continue to be bound by all of the terms contained herein. Any such
extended term shall extend the Post-Termination Period by an equal number of days.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
<U>Disability</U>.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) If
the Employee shall be disabled so as to be unable to perform the essential functions of the Employee&rsquo;s then existing position or
positions under this Agreement, INTENSITY may remove the Employee from any responsibilities and/or reassign the Employee to another position
with INTENSITY during the period of such disability.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b) If
any question shall arise as to whether during any period the Employee is disabled so as to be unable to perform the essential functions
of the Employee&rsquo;s then existing position or positions, the Employee may, and at the request of INTENSITY, submit to INTENSITY a
certification in reasonable detail by a physician selected by INTENSITY, to whom the Employee or the Employee&rsquo;s guardian has no
reasonable objection, as to whether the Employee is so disabled or how long such disability is expected to continue, and such certification
shall, for the purposes of this Agreement, be conclusive of the issue. The Employee shall cooperate with any reasonable request of the
physician in connection with such certification. If such question shall arise and the Employee shall fail to submit such certification,
INTENSITY&rsquo;s determination of such issue shall be binding on the Employee. Nothing in this Section 13(C)(b) shall be construed to
waive the Employee&rsquo;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993,
29 U.S.C. &sect; 2601, et seq. and the Americans with Disabilities Act, 42 U.S.C. &sect; 12101 et seq.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.
<U>Certain Termination Benefits</U>. Unless otherwise specifically provided in this Agreement or otherwise required by law, all compensation
and benefits payable to the Employee under this Agreement shall terminate on the date of termination of the Employee&rsquo;s employment
under this Agreement. Any equipment purchased by the Company for the employee including lap top computers must be returned to Company.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.
<U>No Right to Continuing Employment</U>. The Employee agrees that nothing contained in this Agreement shall be construed to give the
Employee a right to continuing employment beyond the Termination Date.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Litigation and Regulatory Cooperation</U>. During and after the Employee&rsquo;s employment, the Employee shall cooperate fully with
INTENSITY in the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on
behalf of INTENSITY which relate to events or occurrences that transpired while the Employee was employed by INTENSITY. The Employee&rsquo;s
full cooperation in connection with such claims or actions shall include, but not be limited to, being available to meet with counsel
to prepare for discovery or trial and to act as a witness on behalf of INTENSITY at mutually convenient times. During and after the Employee&rsquo;s
employment, the Employee also shall cooperate fully with INTENSITY in connection with any investigation or review of any federal, state
or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Employee
was employed by INTENSITY. INTENSITY shall reimburse the Employee for any reasonable out-of-pocket expenses incurred in connection with
the Employee&rsquo;s performance of obligations pursuant to this Section 14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>No Assignment</U>. The Employee acknowledges that the services to be rendered by his pursuant to this Agreement are unique. Accordingly,
the Employee shall not assign any of his rights or delegate any of his duties or obligations under this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16. <U>Severability</U>.
Subject only to the reformation of time, geographical, and occupational limitations as set forth in the next section, all of the
terms and provisions contained in this Agreement are severable and, in the event that any portion or provision of this Agreement
(including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be deemed
unenforceable or invalid by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such
portion or provision in circumstances other than those as to which it is so declared unenforceable or invalid, shall not be affected
thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.
<U>Reformation of Time, Geographical, and Occupational Limitations</U>. In the event that any provision in this Agreement is held to
be unenforceable by a court of competent jurisdiction because it exceeds the maximum time, geographical, or occupational limitations
permitted by applicable law, then such provision(s) shall be and hereby are reformed to the maximum time, geographical, and occupational
limitations as may be permitted by applicable law.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<U>Specific Performance</U>. Both parties recognize that the services to be rendered under this Agreement by the Employee are special,
unique and of an extraordinary character, and that in the event of breach by the Employee of the terms or conditions of this Agreement
to be performed by his, INTENSITY shall be entitled, if it so elects, to institute and prosecute proceedings in any court of competent
jurisdiction, either at law or in equity, to obtain damages for any breach of this Agreement to enforce the specific performance thereof
by the Employee, or to enjoin the Employee from engaging in such activity, but nothing contained herein shall be construed to prevent
such other remedy in the courts, in case of any breach of this Agreement by the Employee, as INTENSITY may elect to invoke.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Connecticut Law; Choice of Forum</U>. This Agreement shall be governed, construed and interpreted by and in accordance with the laws
of Connecticut, without reference to its principles of conflicts of laws. Any actions concerning enforcement of this Agreement or in
any way relating to the subject matter of this Agreement shall be litigated only in Connecticut state or federal courts of proper jurisdiction
and venue. Each party hereto expressly agrees to submit to such jurisdiction and venue for the purposes of this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Entire Agreement</U>. This Agreement constitutes the entire agreement of the parties hereto, and replaces all prior agreements, promises,
representations and understandings between INTENSITY and the Employee whatsoever concerning the limited subject matter hereof (other
than stock purchase or other equity arrangements). There are no other agreements, conditions or representations, oral or written, express
or implied, which form the basis for this Agreement.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Assignment; Successors and Assigns, etc</U>. Neither INTENSITY nor the Employee may make any assignment of this Agreement or any interest
herein, by operation of law or otherwise, without the prior written consent of the other party; <I>provided, however, </I>that INTENSITY
may assign its rights under this Agreement without the consent of the Employee in the event that INTENSITY shall effect a reorganization,
consolidate with or merge into any other corporation, partnership, organization or other entity, or transfer all or substantially all
of its properties or assets to any other corporation, partnership, organization or other entity. This Agreement shall inure to the benefit
of and be binding upon INTENSITY and the Employee, their respective successors, executors, administrators, heirs and permitted assigns.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<U>Modification</U>. No waiver or modification of this Agreement or of any covenant, condition, or limitation contained herein shall
be valid unless in a writing of subsequent date hereto and duly executed by the party to be charged therewith and no evidence of any
waiver or modification shall be offered or received in evidence in any proceeding, arbitration, or litigation between the parties hereto
arising out of or affecting this Agreement, or the rights or obligations of the parties hereunder, unless such waiver or modification
is in writing, duly executed as aforesaid. The parties further agree that the provisions of this Section may not be waived except as
herein set forth.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
<U>Section Headings</U>. The section headings contained in this Agreement are for convenience only and shall in no manner be construed
as part of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
<U>Waiver of Breach</U>. The waiver by either party of a breach or violation of any provision of this Agreement shall not operate as,
or be construed to be, a waiver of any subsequent breach thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.
<U>Notices</U>. Any and all notices required or permitted to be given under this Agreement shall be sufficient if furnished in writing,
sent by certified or registered mail, return receipt requested, in the case of notice to INTENSITY, to INTENSITY principal executive
offices, attention: President or in the case of notice to the Employee, to the most recent residence address of the Employee appearing
in INTENSITY&rsquo;s records, or to such other address as such party may specify in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.
<U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall
be taken to be an original; but such counterparts shall together constitute one and the same document.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Agreement on the day and year here above first written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INTENSITY THERAPEUTICS, INC.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lewis H. Bender</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 37%"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Agreed and Accepted</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Joseph Talamo</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Schedule
A</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
Salary: Three hundred and seventy thousand dollars ($370,000), paid at a bi-weekly rate of $14,230.76, subject to tax and other customary
deductions in accordance with the Company&rsquo;s normal payroll procedures.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus:
Subject to the approval of the Board of Directors you may be eligible to earn an annual discretionary bonus of up to 35% of your base
salary. The amount of this bonus is based, in part, on your performance and the performance of the Company during the calendar year,
as well as any other criteria the Company deems relevant. The Company will pay you this bonus, if any, no later than March 31st of the
following calendar year on a pro-rata basis.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacation:
unlimited; however, you must obtain approval of any days taken in advance by your supervisor (CEO); there are 10 paid holidays.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
Options subject to final board approval: Eighty Thousand (80,000) incentive stock options per our employee option plan with a vesting
schedule as follows; 25% at 1 year from the start date, 25% at 2 years, 25% at 3 years, 25% at 4 years.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
without Cause: </B>Following 3 months of employment, should you be terminated without Cause (defined below), or by your resignation for
Good Reason (defined below), the Company shall pay you, as a lump sum severance payment, subject to tax and other customary deductions,
at the time of such termination, an amount equal to 1 month of base salary during your first year of employment and an additional 1 month
of base salary following each year of your employment anniversary, up to a maximum amount of 6 months of base salary, provided that you
provide the Company with a fully-executed general release of claims in a form satisfactory to the Company and allow such release to become
effective by its terms (the &ldquo;Release Requirement&rdquo;). You must be actively employed full-time in order for any such payments
to be made.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
there is Termination &ldquo;For Cause&rdquo;, as defined below, then no such severance payments will be paid.</FONT></TD>
</TR></TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
For Cause: </B>Termination for Cause (&ldquo;Cause&rdquo;) ensues when the employee&rsquo;s actions are against Company policy, illegal,
or may lead to serious repercussions for the Company, its employees or corporate partners. Termination of employee services with Cause
may be necessitated by a serious violation of the company&rsquo;s code of conduct, inappropriate disclosure of confidential information or
trade secrets, or continuous poor performance as determined by the Board of Directors. Cause also includes dereliction of duties, poor
relationships with other employees, sexual harassment, or treatment of external parties or partner companies that results in negative
outcomes for the Company with such parties.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 11.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Termination
                                            for Good Reason:</B> Termination for Good Reason shall be defined as; a significant reduction
                                            in responsibilities or authority as an executive, a decrease in material benefits or compensation
                                            not due to financial distress of the Company, relocation of Company&rsquo;s current corporate
                                            offices to more than 50 miles further away from your current home. You will have to report
                                            an such an adverse event within 60 days. A Good Reason termination requires you to give prior
                                            written notice before terminating for Good Reason 30 days in advance.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Change
in Control: </B>If there is a Change in Control of the Company (as defined below) and your employment is concurrently with such Change
in Control or within six months after such Change in Control terminated (i) by the Company without Cause, or (ii) by your resignation
for Good Reason, then in addition to your rights under the Company&rsquo;s employee benefits plans and in addition to your right to receive
your accrued but unpaid Base Salary and your expense reimbursements, the Company shall pay you, as a lump sum severance payment, subject
to tax and other customary deductions, at the time of such termination, an amount equal to 4 months of base salary following your one
year employment anniversary, 5 months of base salary following your second year employment anniversary and capped at 6 months of base
salary following your third year employment anniversary, provided that you provide the Company with a fully-executed general release
of claims in a form satisfactory to the Company and allow such release to become effective by its terms (the &ldquo;Release Requirement&rdquo;).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of this Agreement, a Change of Control occurs for purposes of a Company stock plan in accordance with the definition
contained therein, and for all other purposes a Change of Control occurs if: </FONT>i) one person (or more than one person acting as
a group) acquires ownership of stock of the Company that, together with the stock held by such person or group, constitutes more
than 50% of the total fair market value or total voting power of the stock of such corporation; provided that, a Change in Control
shall not occur if any person (or more than one person acting as a group) owns more than 50% of the total fair market value or total
voting power of the Company&rsquo;s stock and acquires additional stock; (ii) one person (defined for the purposes of this paragraph to
mean any person within the meaning of Section 13(d) of the Exchange Act), or more than one person acting as a group, acquires (or
has acquired during the twelve-month period ending on the date of the most recent acquisition) ownership of the Company&rsquo;s stock
possessing 50% or more of the total voting power of the Company&rsquo;s stock; (iii) a majority of the members of the Board are replaced
during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the Board before the date
of appointment or election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Benefits:
Participation in our group insurance such as medical and dental in accordance with the terms and conditions of each plan.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retirement:
Participation in the Company&rsquo;s 401k plan with 3% match.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holidays:
10 paid holidays (below) per year, the exact dates to be set each year.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: justify">For 2023:</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
                                            Year&rsquo;s Day</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin
                                            Luther King Day</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President&rsquo;s
                                            Day</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Memorial
                                            Day</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independence
                                            Day July 4</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labor
                                            Day</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thanksgiving</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Day
                                            after Thanksgiving &ndash;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christmas
                                            Day &ndash;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Wingdings">&sect;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Floating
                                            Holiday &ndash; Chosen by Employee</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Schedule
B</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Chief Financial Officer will serve as an integral member of the executive management team, reporting to the CEO. Incumbent will be a
closely allied financial, strategic and operational partner with the CEO in supporting Intensity&rsquo;s drug development and commercialization
efforts over the next several years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CFO will lead the execution of our c financial reporting, cash management, budgeting, stock option and warrant management, SEC interactions,
including the philosophy for long-range portfolio and organization planning, corporate partnership strategies, in collaboration with
the CEO the corporate fund raising and investor activities and functional execution of these plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position
Responsibilities Include:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infuses
discipline, innovation, and momentum to Intensity&rsquo;s financial and business operations, strategic planning and corporate development.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Together
with the Principal Accounting Officer, works directly with the company&rsquo;s auditors, accounting and tax firms to achieve proper financial
controls and reporting while minimizing costs,</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plays
an important role in driving long-term financial objectives of the company, a task involving all necessary preparation and representation
of the company to institutional investors and managing the capital markets strategy.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Helps
to establishes and develop strategic partnerships, joint ventures, or collaborations on internal programs in concert with the overall
corporate plan.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
collaboration with CEO, research and outside counsel, develops IP strategy and process.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
strong financial management across all aspects of the company and leadership of business/financial planning, reporting, and analysis
as the company continues to evolve.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identifies
and supports strategic business opportunities (Corp Dev and Bus Dev): relationship sourcing, establishment of diligence room and core
positioning, asset diligence, negotiating, and contracting.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accountable
for the financial and capital strategy.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defines
and establishes NPV estimates, budget projections, financial models and update as needed.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Builds
and refreshes corporate deck for investor interactions and messaging, drafts or works with IR/PR firm to draft press releases.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Responsible
for the 10Q and 10K documents and all SEC or governmental filings (e.g. taxes).</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
CEO, represents company externally at investor, business, and other conferences.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leads
interactions with external stakeholders that support internal development efforts.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drives
additional corporate projects as needed.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualifications:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum
of B.Sc. degree in accounting or finance with a CPA.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10+
years of successful progression in life sciences as a CFO.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Life
sciences background is highly desirable.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accomplished
financial executive capable of directing the managerial economics of the company&rsquo;s operations and serve as external representative
with institutional investors, market analysts, and potential industry partners.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
and banker contacts a plus.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
track record in clinical stage company strongly preferred.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excellent
interpersonal and verbal and written communications skills with a high degree of attention to detail and quality.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstract
problem solving, and strong negotiation skills required.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comfort
with financial modeling or review.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adaptability,
flexibility, independence, and resourcefulness to both lead a big vision strategy while also willing to roll-up-sleeves and multi-task
to thrive in a growing environment.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
have both large and small biotech company experience.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ability
to hold oneself and others accountable for commitments in a positive and effective manner.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea189864ex99-1_intensity.htm
<DESCRIPTION>PRESS RELEASE, DATED DECEMBER 12, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intensity
Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mr.
Talamo brings over 25 years of experience leading financial strategies to support both publicly</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>traded
and privately held, development and commercial stage biopharmaceutical companies</I> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHELTON,
CT, December 12, 2023</B> &ndash;&nbsp;Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on
the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune
system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be
working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience
in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell. Mr. John
Wesolowski will remain as the Company&rsquo;s Principal Accounting Officer and Controller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
am delighted to welcome Joe to Intensity, his wealth of experience as a biotechnology executive and track record of success in leading
financial operations will prove invaluable as we transition to a late-stage clinical company,&rdquo; said Lewis H. Bender, President
and Chief Executive Officer of Intensity. &ldquo;I look forward to leveraging his versatile experience as we pursue our goal of treating
solid tumors with our lead asset INT230-6.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
CFO, Mr. Talamo will develop and implement Intensity&rsquo;s financial strategies and lead financial reporting, finance corporate development,
strategy and investor relations efforts while supporting the Company&rsquo;s overall business goals. Most recently, Mr. Talamo served
as the CFO of HiberCell, building the financial and accounting function, and overseeing the evaluation of financing and strategic initiatives.
Prior to HiberCell, Mr. Talamo spent ten years at Caladrius Biosciences, a clinical-stage biotech company dedicated to the development
of cellular therapies, most recently serving as CFO. Before his tenure at Caladrius Biosciences, Mr. Talamo served as Vice President
and Corporate Controller for OSI Pharmaceuticals. Mr. Talamo holds an MBA in Finance and a BBA in Accounting from Hofstra University.
He also is a CPA registered in New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;I
am thrilled to join Intensity at this pivotal time in the Company&rsquo;s evolution as its lead candidate INT230-6 is anticipated to
enter a Phase 3 clinical trial,&rdquo; said Mr. Talamo. &ldquo;Intensity&rsquo;s novel intratumoral delivery technology is at the forefront
of innovation. I look forward to working closely with the team to advance Intensity&rsquo;s financial strategy and further its mission
to improve the lives of patients who are impacted by the debilitating effects of cancer.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
INT230-6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INT230-6,
Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was discovered
using Intensity's proprietary DfuseRx&#8480; technology platform. The drug is composed of two proven, potent anti-cancer agents, cisplatin
and vinblastine, and a penetration enhancer molecule (SHAO) that helps disperse potent cytotoxic drugs throughout tumors for diffusion
into cancer cells. These agents remain in the tumor resulting in a favorable safety profile. In addition to local disease control, direct
killing of the tumor by INT230-6 releases a bolus of neoantigens specific to the patient's malignancy, leading to engagement of the immune
system and systemic anti-tumor effects. Importantly, these effects are mediated without immunosuppression that so often occurs with systemic
chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Intensity Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intensity
Therapeutics is a late-stage biotechnology company that applies novel engineered chemistry to turn &quot;cold&quot; tumors &quot;hot&quot;
by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment
of the tumor. As a result of the saturation, Intensity's clinical trials have demonstrated the ability of INT230-6 to kill tumors and
elicit an adaptive immune response within days of injection, representing a truly novel approach to cancer cell death that holds the
potential to shift the treatment paradigm and turn many deadly cancers into chronic diseases. For more information about the Company,
including publications, papers and posters about its novel approach to cancer therapeutics, visit&nbsp;www.intensitytherapeutics.com.
INT230-6 has completed enrollment of over 200 patients in two phase 2 and phase 1 dose escalation clinical trials (NCT03058289 and NCT04781725)
with various advanced solid tumors; IT-01 in metastatic disease, and IT-02 the INVINCIBLE study, in presurgical breast cancer. The Company
partnered with Merck Sharpe &amp; Dohme (Merck) to evaluate the combination of INT230-6, Intensity's lead product candidate, and KEYTRUDA&reg;
(pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell
and bile duct malignancies. The Company also partnered with Bristol-Myers Squibb to evaluate the combination of INT230-6 with Bristol-Myers
Squibb's anti-CTLA-4 antibody, ipilimumab, in patients with advanced liver, breast and sarcoma cancers. Intensity managed the individual
combination arms separately with each respective partner via a joint development committee. The Company also executed agreements with
the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to study INT230-6 in the INVINCIBLE
study, a randomized controlled neoadjuvant phase 2 study in women with early-stage breast cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements in this press release may constitute &quot;forward-looking statements&quot; within the meaning of the United States Private
Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to
the expected future plans, development activities, projected milestones, business activities or results. We have based these forward-looking
statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially
from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties,
many of which are beyond our control, include: the risk that the anticipated milestones may be delayed or not occur or be changed, as
well as other risks described in the section entitled &quot;Risk Factors&quot; in the Company&rsquo;s SEC filings, which can be obtained
on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only
as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company
does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this
press release except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argot
Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
Nugent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intensity@argotpartners.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argot
Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Rosen</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">david.rosen@argotpartners.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X .P# 2(  A$! Q$!_\0
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M=OO_ !/JBBH[>>*ZMXKB%P\4J!T8="",@U)72=H4444 %%%% !1110 4444
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MJM+8])1%C1410JJ, #H!3J**V/0"FR1QS1M'*BNC##*PR"/<444 <CJ7PO\
M"6IRF5]+6!SU-LYC'Y#C]*I6_P 'O",$H=K:YFP<[9)S@_EBBBE9$>SAO8Z_
M2]&TW1;?R--L8+6/N(D S]3U/XU>HHIEI6"BBB@ HHHH **** "N>\41W'_$
MN>WO;NW,EW% X@< %&/.>#S[T44&=17BQNJWFJV6KVUOI\/VI/L<A=99O+Y!
M4!L[3D]:P[[5K]="\,2RWLD)N8B;ES/Y.YO+!&7VG'/MS110<U9N*D[_ -71
M=U>[O?LNA)8RWEPLPD:06MPN^3;'G[Y !Y]AFGRZM?IX(LFCEFN=2O0(D>!
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M1^-%%(TA[TY1>VAR&C_!+1;&Z2?4+R>_"'/E%0B'ZXR2/QKTY55$5$4*JC
3& !110DEL;1A&/PH6BBBF6?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ints-20231211.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWamEeaPtyJ1xmYkxuG96falavygkcnAOhi7xKqiWUYAP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:INTS="http://intensitytherapeutics.com/20231211" elementFormDefault="qualified" targetNamespace="http://intensitytherapeutics.com/20231211">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://intensitytherapeutics.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ints-20231211_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ints-20231211_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ints-20231211_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ints-20231211_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://intensitytherapeutics.com/role/Cover" xlink:href="ints-20231211.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://intensitytherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140088746961280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 11,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Intensity Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001567264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1488089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Enterprise Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Shelton<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06484-4779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">221-7381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INTS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea189864-8k_intensity_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ints-20231211.xsd" xlink:type="simple"/>
    <context id="AsOf2023-12-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567264</identifier>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2023-12-11">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-12-11">0001567264</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2023-12-11">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-12-11">2023-12-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-12-11">Intensity Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-12-11">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-12-11">001-41109</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-12-11">46-1488089</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-12-11">1 Enterprise Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2023-12-11">Suite 430</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-12-11">Shelton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-12-11">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-12-11">06484-4779</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-12-11">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-12-11">221-7381</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-12-11">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-12-11">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-12-11">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-12-11">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-12-11">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-12-11">INTS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-12-11">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-12-11">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2023-12-11">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3$",5ZK$(A8S 0  (@(   \
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M4$L! A0#%     @ 3$",5SNCF37M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 3$",5YE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !,0(Q756T'JY $  #5$0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 3$",5Y^@&_"Q @  X@P
M  T              ( !T@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !,
M0(Q7EXJ[',     3 @  "P              @ &N#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " !,0(Q7JL0B%C,!   B @  #P              @ &7$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 3$",5R0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 3$",5V60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea189864-8k_intensity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intensitytherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea189864-8k_intensity.htm">ea189864-8k_intensity.htm</File>
    <File>ints-20231211.xsd</File>
    <File>ints-20231211_lab.xml</File>
    <File>ints-20231211_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea189864-8k_intensity.htm": {
   "nsprefix": "INTS",
   "nsuri": "http://intensitytherapeutics.com/20231211",
   "dts": {
    "inline": {
     "local": [
      "ea189864-8k_intensity.htm"
     ]
    },
    "schema": {
     "local": [
      "ints-20231211.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ints-20231211_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ints-20231211_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://intensitytherapeutics.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea189864-8k_intensity.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-11",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea189864-8k_intensity.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-23-094884-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-094884-xbrl.zip
M4$L#!!0    ( $Q C%?4TK=5(QH  /B2   9    96$Q.#DX-C0M.&M?:6YT
M96YS:71Y+FAT;>T]_7/:NK*_,\/_H,NYYTPZ+WQ#$I*4.P1(2CY(#I"FIV_>
M9(PM0(VQJ#\(]*]_NY(--M@AI(2VN3T];0*6=E>KW=7N:B4?_V<RU,F8FA;C
MQOM$-I5)$&JH7&-&_WW"L7O)@\1_RO'8\<"&=M#6L-XG!K8].DRG'Q\?4X_Y
M%#?[Z6RI5$I/L$U"-CJ<A+;+93+9]*>KR[8ZH$,ER0S+5@R5SCKIS'B(AH]/
M9TV[ILX"3?$;#TD^O00:GFKS#O[&>VGY,-#4#FU:E$UMKRFS>"&7W7^*#MEB
MUF$2U3:+-,,(Z:>3UN6\N1W>?MXT;9N*8?6X.51LF$.$5$QF<LG<G@](TJ)J
M !!\3O7Y>"6<@V0^Z\%9FIS@2/%Q5[%F'-?H KL]G/  >N3R7D.3]B+![J7A
MJ=?0L9)]11G-&O<4JRL:N@\"4.$[D^O4"FTMG@2:J]PQ;',:3K'[,-#!,NUE
MT/!EH%&CV6G/6C'#IH;%[*D]H*8RHH[-5"NE\J'HDLUELPFA:531X"?!_XYM
M9NNT?)R6/^'ID-H*08!)^M5AX_>)*D>P=K(S'0'K5?GI?<*F$SLM%3*-_=(N
MV.-_)9/DE%%=.R1M:A^1IC*DAV2B38Y(HR9^N<_DJO>W[3]SM;-*Y09^('DD
MF7QN[_SI/8[[/G*\]]YXUP!:.)GU>DGW8NF>@MS!8.#_RI :&ORU3W6E?]]3
M=(NN ZKN U4W8&:F58!E*GK#T.CD@D[O,V#FBGO[N;W"&G#W3H#IM?OLO6LR
M) +X:AT8N?OV0#&I=9^[%Q92 K'$=^O J2$M-RZL_!))D<"[7)L2RY[J]'VB
M![)X2+*9D4TZ; A-FO21M/A0,7;E%[M @,EZ0NHU-O;Z:<P:Z<KTD!C<H.(A
MFQRB^%(3]4)\8II&#:$E^!$:-ITAP%*E DSL%MJ4BG7=0UE)9G-)4"YBP$@!
M/&6' 0E(E(4('*<#D%X./%0F$N6Y4(1B2@>&A8C!\E$3%F-JR19H8 \ML7("
M!40LAX<#83U!U:RDIQ:IB:4EW,<V6(7W"8L-1SJ5EL!%%00NT5G<,3ULT$S,
M\:$[9L*TI3%[5LIK2L7 9]_.OF<:/NDQ:A)!/@U=BJJ-BR"3%CO/T:5#\;G8
M1L!3KBU3 ?Z :=<4FY;G0_ @S9\M=0-!B>CD/5DD*T" ]Z7+QB!O'8-)QH)*
M+7%S2!7+,6G9U;U#:.,!\QX%42"T"/A2D2-1N$P0C5Z,8VXPEO" <L,T+O,6
M^PHE4&QN^AZOSX-%&L.@^I#6J,&'S%B%=C5?%O&& ?:>![BPQ%!7*WTZ*$V"
M9_>.T] ??N*?X]&Z-O:(#!6SSXQ#@DTS"7 I1@*8?SEH.3I-WBA]L1KZ+;+L
MF[3Y2/3W@"6[W+;YT/WND6GV &G)_)D(].YR$X8@>Y_HBOI <D"#Q76F'1'W
MH0=)/L_.G^, DQ;[!DL4?)LH__5'=B]S))GA_NL;03HPA VQRD,YV@S (X*&
M(*GHK ]?J6#$J D,ZY9OFXU.O4;:G4JGWCY.=\NOC[)=K]ZV&IU&O4TJS1JI
M?ZI^J#3/ZJ1Z?775:+<;U\WMT'%7:7]H-,\ZU\U=4DM54R27*19*6\"]K;D]
MO6Y=D6-KI!C"5J*35<K4A".93-:XZJ S@B[\O3IS<^<.[[?J6>VR?]ILW-Q\
M 7 O<4K\.!+E@^3%HA-RG$;JRF^(YR#:K7JS0UKUF^M69SN"?..8EJ,8-K$Y
M=%0QDB;9/.$FR19WM'?;(8+W"(1<B-\QF<T 8'VB#A0#K&)%M0D\SI;RA3<T
MT^B&X;!:=,1-F^QXGZD"2RRU;$+'T)B8XC'5WAT",0NZ>+*@BS?"B:M+%R]<
M*9OG^V;Q8W%8J3VLI90RQP).^\0^U #Z$-H.-&4Z!7*I$::T 6(2Y1I5Z; +
MWG0VNTL0\EO793%7/LB>0Y!#CP#F?W$R*^YDRDBL1?O,PNR6C:%N^%QV/Q\T
M:Z5,WL[LO]# AN%*E!M>#H1T?$F07=(PU-23L^;^^MJ:LU.?*& 2<!A2@3SR
MB6*1]HBJ&'EIA!FD85OQ6!5<8>BZ%3NV*?!+0FHK79T"'ET')JLBT9U)B,\C
M1=.\SVLC]?F_,[=6Y;JNC"R05>\W&1L=VZ:'8$Q-$ E%]\8/;K(7/QW;VH(/
M[;G)7>DFIXIS1]E%G\_]N:8292*4J!A0(A!8;H+Y%,GAM@UVJ"J3HE6N1>C4
M-VUX<LT&NGX^>*E]Q+PU!N<V'9E\C%(:-)#/H W-I:X\@FE]CK[9VC+O7<[F
M_IQ+4EBS'S!%^X$I.F4ZA;'!PA ^'X/B625W<?&X=[/>?"RR>XX'\S799"&;
MS93>'G,+ >9VE$G#S42I0LZ>XG3E?/]+(],XRVJ][^)T!-)$N;"7S!8.#C('
MS^4[_&.N9WF\WUYOZ1&:BJ[Q-6X0D'-P5BV-"9_YN&N*9"4L20'EGBT\02EY
M4G1>) P[53X<,@MW125L%'HBV?\N4JA#Z7A]1C9:;5(?CG0^I:;'N:#<D"9/
M!7DW%XBT6 _+OU?:-2U-H?1GXM7G=M$HY0)&J:)I)K4L]\<E,V@VW"#9V7&K
M>#XJ[CUJWV600A FREE21WI'H+Z4U$PVCEII=Y<R(*<KAI,+'\[7BY.[1K9]
M-=8W/)I<HMQV&%BE0CZS,JC:[LSGPUA5A5^OS0Y_-,(9U:[5<G]?EXSBY4;F
M?8X.^#2@N@V6^KE3'2JY8@FX-F_ N6.&&N%'7E">.]%KM<_L8!.#6,"9*%<[
M*Z9ZA>?R=&3\,F]FT5;)IG[;LR$O)U0#;SCXW/IG-HIV[K]\8Y=<J=WQKQN9
ME !&<"OW"@>%9&%___7\F^]S#URR,6:^,4&,V$C127U"58COQY1<]V#EI5:T
MI_ 4]LT[,\!7@HQ=HN<UO(!(B^:-:QLIT)TH\XDFK&)2)5JRS[7]_L?FA^Y5
M7WVA9/MQ),JY3%1^[MV2D?1BCDL.<GLSX,:3 =U!\XQ]/FBP+[<OI701#U";
MRR;W\P?9'Y=2Q-F;YZ'^^N,@E]T_LDB'ZG2$E+I>N,BAZ0YZD?$8<MLOX6\@
MY^F:ZG*3VZ0R&NE@R4!!MSL-I]R$V1<50ABGN1]=V[=+6(]4Q;:"1MJXE,9C
MEXIENUGX7WXF=-H#\UD=4%B;<3M%&8U,#DXN!JU=/B%=JO-'Y $^1-:0@^1%
M/-9C.H@D8181]6\:,,?FQ&)#1[<5@W+'TJ?$@JC,ZDU%5[<#[P):&:RY^S?F
M/!GK !R3*,;4>]:#((<_8C],C#&,4RVR8U%*SJA!346'"-" SHX(IRU22>52
MDN)WA]O(K/KCN\7X[X5(URH_>-(+",[S%\>"0'DJ"LV6O+M,*E=D1IA@+*^Z
M/67(].GAJM$LK] 1B=<[D]D@09B)< PWD+?"5X*:]G>FG?N2TVC^Q5M17<YU
MJABB%LZ_1H22@5-?VB\4CB+7"9^3$>Z^S/C^M/_BHH=A^/&3D;O1&H^!=F'5
M!RGDBJZ>+&Q^XI[G3G:?5$];))?/I*#ANZ!3)MR@#;I \M_4?M%?L?);1S:H
M(UE71]H0+JDPS4;_"NPR&&<]8J_VXTC[</'Y<[^P7@'%<Q1DF8;M:<<<-TRX
M1!ZB&MF" @/R:4>@'F"F&X5,2K;\K1Z_N'IXT<Z-2=%N8YVO*/Y!?\2$X#0J
MHNB/3RRU-1T>?"AN7$VB:=F>N@ -2=5'Q,*J$H^-?/4[KNIHR=Q.]]WSE$>V
M_:T^O[CZ'(2K3\.R'&JN5*(O%_72?B/7KNF;=\964?13JU*>)@L[ZO-4R6W[
MRJJT\1 25N2YXRD#.&I""#@*JPL4=L4-Z( !6PG,WM)&W(HD^<M+ 3IXV@YG
MIJZH U+5%<LZ?'XEPP_8#_B.H9H*SC]I3X==KN]8[W[P0+][0$VWE&UF6D#3
M[@8,YK$U4\>E,3YS^P"$' CNFQPL& HZ-P_)']5JO7YZNJF=A:AM,]>L3+.Y
MKI#."/^MGVOS?J:3O^V_,".\B"=1QO4&>-BVN?JP2_Z=2>$9+3)23#)6=(>2
M$1[K&GQ'?=56]D"B]KU<^9?B'\[4X<U^-<._??AZ\T*>!G DRG@X]N?G5;D#
MJ](BUS(+TN@I671A;>G37H'>YC-.=;W"VL4B0 J8ENO_PNA(E)N5=JWR=P2+
MI2"3*\5\H#:YO*RNW%'\B=V-,+>X86CHA%'2G1)59*^ARP-Y'%!19A7,+,=C
MS"(PQ>#"(=@^ >/V: _0F1MANEFQB$9[S) UP#+/EBF2Y1,&\X,%>;*#H]P_
M$KDVKS&@@2D:8?$P;B5(AS#73>9<6/'8BN,*,ZCH'<X[^N"F7I6M6YBY>O@D
MN)A?%NTL!S>EP(Z_A_-,H*Q*C.&JG.WO33],N3/6U]MN#(EK;-.AR[4 H;2X
M$<W>RHCFUY[[1N\)-=P%Y9LI=3SFTVJVM%4T )6E.H08H+(&%P&'8U'1"I"Z
M&U)XU0<308@\K(QS))#I4\3^R  WJK\!XX$G)ATS"_J!(5 ,E>'NDJ**2S&P
M-5ZTHBFF9LF]*"TJW,GO*+-PQZ_A*;(QV0X62=4GG=E Y1&:B,+HNT;W@UGH
M["O?G?6*$.PE0K8MU4LR_".._?J.]88>^_4="WY[QWY])UI\E"/-1]#^JX-Y
M%  K!R"\N&5>+IR2]L=-_KG"<U%+D[4GG+M1<&X%;?ZA>J?,EP@PJ?*0[%(0
M>:!R)*CVH]P+P>@>SUH+I7]2-SR?'OLW/9LO!K5"L=SO<'F ;V8I4%@)J!'X
M9KV\W4(AUH;,S \;2\.F0SF>8BJ32\5C-0JAJ>V8(@E08R:L/MRT<!6K0D"O
M@!<KB_-,ZXC4=7=M\C<]PG(;S@Q;9#7AR7(_=$VH8>$M#U-2,4U<R;"UY6L>
MCWGM4TN<WH 'L9R(>!PP/!QZS&;SRS;I%3V%<(%AY]RBHP'I*+HRY%LD8[OC
MOC;(TD%<+$H+._ 9C^V@UX/%;+G,4=7SZ^%3]NC=+I86(?_ <0JP3A0.47-,
M,0S#_M4!HSVPCZX7YDFDYU2Y< GM]5"NH=\2@: @-^!_F CZ"^!$_\W7=9?T
M3#XD%:</"H@=,@2=/)TT^5@"DJ.\,E,NC4 \6.EB85=2JHESH]1 %!^!-G)C
M4DM<X0/^I+8X@)F.X @^,(!?I;HN3\<"8*+JS! I.' Q 4N7<9NJ P.FH3^=
MA:@:'5.=C]R1S%B.(U3<*ET5;P)$-U;DHP4E>(\:0+68E2*G,.9X[-PQ* PO
MFW6'?.[H4\$"_W#)([K7\JR-AA'V)0,SH(2<[B4[/5$N!T >#/YH(&.J $,S
MF6.1$\8ME8G[EW:Q5$M-O<,(':P63(;+23 Y8P4F"YJ+^^HP"G K'F&^Y)DH
MG#EP.KFNB_HPC\.5N7?N<GA7/ 4&&43'0H&92,UE$<LL,0Q_YN1YD%-^]H -
MI4R( 3E)G:0J*1R%CQHA7A]X#X,5<FLP<?.D/974@:6_\CK%8Q(1C>H20(M)
M#&%XY7'E&Z>K@^_NXL4X!*@0"0O;O1D M?\?;CYL,F<0:2DV'CY&8NH($5+@
MKP'2'UB83+GM)H(UF F8Z2ZU'RG( _!14N@R4T[%E'"1+X( T<(XT1?1/8IT
M.K 3E<'R@DU%))+X@KC-R9$AG5!"L4,X8".+N#3$8Y%$],+$E&C^A9W.ZNZY
MM^0N#0K#8B!"]L-.&%&+WV=U,VB!0> Q)V8(W'0"0;6HS83@V#%-8"0, *M
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M.A>[CY_L[N^L)9'5L_XDHOGVB/HV5[RW PO\XP4?'%+I\_M_O-AI"$K,5:F
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MW(QMU[S]7%XH5C-.P"2T>Z4*CQH6 6?DK]@1;S2%&@2KR?'(GR,9-F7-!;Y
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MEH/U HH)XZ'P823^TOA,+/LO=48/[Y21X@O#=X$>YFGA[L!)>+X)'80NW3V
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M%<FHJ$DY^1S3VN23V(*;>4<XR :L*F%J.<>F\>DTS=ATP](I"5XZR&_._[D
MHLV-&@P1:(SAPWM,.3>P0)/2Y=6\W3$>.<-C\+^^H(/]RQ=TL0.'C'D /##,
M"4]3YQ4U077QRT &=TH&3]@-/Z"&!-=P$'9T'>1+'T5KE1FX^I4+;J\PG*G
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M,$B!XNEUIP*M[9QS6:@F)G2M?!0\;69%?A!)ERSM V6.MPY"Q!.UU%8&K\2
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MS%2@.K ZC9&J8#]3:N]'@KTFE87%(QTRDQD6N*REM?8(L^YV,GH5]F@ZIJ
MPT4*?&5I;ZH2A(6.&&B-NC(Q7Y YM%]D'5F#U5JB2T-9#5NNLN[&MOKX<X@+
M+>ZUU+5:S&=';:P6\'7\'+"\M_5TN]#Q>U7Y41Q(5S7E\U9WL!UY:BHEV<DF
M9'1L?IED=AO,:G.E]S$>_F#@K'<L\!]Y Z$I_.\S!GI1+<-&;C+YFEE<>&97
M=,BBW&#(/[!""1\?V#M;1KTQ2A12096Z+9=EEY&JA%6F9M(6R]M/+<HS\DQ
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ME/1K@#B;=MR@)0A?PF8E4$W:=$2O1Q NI?/P$+.@XX)W+7$+FB6!IT)H5YH
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M_H".HZ84 R\ 3A1"?*@2C!INC'50-_8V$:E*]V"+2\;=_\JW_N^T1($W4U0
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MKD[VSM=I_NCI@"!G]7)JP:I=H[DWWMR@RR(QJ=6SIAA/D +5@"(8< 1EF;K
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MCP9]&0"]W3HKZ/#C*<M:-YI_EV3@LDGD<<U3%OOIQRL X0,=VK1;+QCP)\2
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M;[+B\6 WP9["*I*%6C6N9L]N]!LBO8+LO(<_Y>?X@;R.@'V)OO9?^_(%!]\
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M?W"ZS_K8"LH8)>GTB4)A6SYI$,9-<H3X'EI"&:/DFB%Q*)P'5H\B?"02NOI
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MWS.#\D7,0BMDH>"])N))90L3K^^5C"EUTR=Z>[8!$B)@!="0(.:G+T*!\[A
MIJG;3"3CI_'<BM9WF<G?:VK]"SXT"):#A@9S$R= .-)=D/Z^T8LFU^L'.J7*
M+5-XI"MS;1MZ"M\4 8I#XX/Z1B$PAHHP772/=-W: ^[-M<4W[I=[.ZL]\A]0
M2P$"% ,4    " !,0(Q7U-*W52,:  #XD@  &0              @ $
M96$Q.#DX-C0M.&M?:6YT96YS:71Y+FAT;5!+ 0(4 Q0    ( $Q C%>A\8"\
M:C,   1P 0 <              "  5H:  !E83$X.3@V-&5X,3 M,5]I;G1E
M;G-I='DN:'1M4$L! A0#%     @ 3$",5]:Y0G=]#P  .4$  !P
M     ( !_DT  &5A,3@Y.#8T97@Y.2TQ7VEN=&5N<VET>2YH=&U02P$"% ,4
M    " !,0(Q7RF$9^# #   *#   $0              @ &U70  :6YT<RTR
M,#(S,3(Q,2YX<V102P$"% ,4    " !,0(Q718/B,?T*  " A@  %0
M        @ $480  :6YT<RTR,#(S,3(Q,5]L86(N>&UL4$L! A0#%     @
M3$",5Z&3J(!?!P  [U<  !4              ( !1&P  &EN=',M,C R,S$R
@,3%?<')E+GAM;%!+!08     !@ & * !  #6<P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
